Burgess, B.T.; Anderson, A.M.; McCorkle, J.R.; Wu, J.; Ueland, F.R.; Kolesar, J.M.
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells. Diagnostics 2020, 10, 121.
https://doi.org/10.3390/diagnostics10020121
AMA Style
Burgess BT, Anderson AM, McCorkle JR, Wu J, Ueland FR, Kolesar JM.
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells. Diagnostics. 2020; 10(2):121.
https://doi.org/10.3390/diagnostics10020121
Chicago/Turabian Style
Burgess, Brian T., Abigail M. Anderson, J. Robert McCorkle, Jianrong Wu, Frederick R. Ueland, and Jill M. Kolesar.
2020. "Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells" Diagnostics 10, no. 2: 121.
https://doi.org/10.3390/diagnostics10020121
APA Style
Burgess, B. T., Anderson, A. M., McCorkle, J. R., Wu, J., Ueland, F. R., & Kolesar, J. M.
(2020). Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells. Diagnostics, 10(2), 121.
https://doi.org/10.3390/diagnostics10020121